Sarah Davis, MD
Medical Oncology · Aurora, CONPI 1659576163
Payments from drug & device makers
Across 283 payments — averaging $13,715 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2.3M
- Merck$722K
- Pfizer$289K
- Genentech, Inc.$268K
- Astrazeneca UK Limited$148K
- AstraZeneca$39K
- plus $85K from 6 others
Across 3 payments — averaging $98.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Servier Pharmaceuticals LLC$296
What the payments were for
- Consulting fees$6,51087%
- Food & beverage$95813%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 53 | $2,329,998 |
| Merck | 79 | $721,837 |
| Pfizer | 28 | $288,922 |
| Genentech, Inc. | 57 | $267,942 |
| Astrazeneca UK Limited | 9 | $148,280 |
| AstraZeneca | 18 | $39,145 |
| Halozyme Inc | 7 | $31,621 |
| EMD Serono, Inc. | 6 | $17,270 |
| Incyte Corporation | 13 | $17,182 |
| Trisalus Life Sciences, Inc. | 11 | $17,100 |
| Genentech USA, Inc. | 1 | $1,870 |
| Array Biopharma Inc | 1 | $139 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$3,000
- TECENTRIQ$1,870
- IMFINZI$1,775
- TRINAV INFUSION SYSTEM$301
How this compares
$3,881,307 in reported general payments places this provider in the 90th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 12 | $163,498 |
| CreonLipase/Protease/Amylase | 30 | $107,871 |
| XareltoRivaroxaban | 14 | $7,313 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 16 | $721 |
| LoperamideLoperamide Hcl | 14 | $482 |
| Ondansetron Hcl | 38 | $419 |
| Oxycodone Hcl | 24 | $382 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $363 |
| Omeprazole | 22 | $348 |
| Potassium Chloride | 16 | $301 |
| Prochlorperazine Maleate | 15 | $168 |
| Alprazolam | 11 | $39 |
| Pantoprazole Sodium | 13 | $11 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Aurora
- Karl LewisAurora$12.4M
- Christopher LieuAurora$8M
- David CamidgeAurora$7.3M
- Theresa MedinaAurora$7M
- Wells MessersmithAurora$6.3M
- Antonio JimenoAurora$5.6M
- Elizabeth KesslerAurora$5.1M
- Sunnie KimAurora$3.9M
- Peter KabosAurora$3.5M
- Robert LentzAurora$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.